Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Events
Rare diseases
World Orphan Drug Congress EU 2026
Blogs
Rare diseases
What homecare looks like for three families living with rare metabolic disease
Thought Leadership
Rare diseases
Most Favoured Nation (MFN) & International Reference Pricing (IRP) for Orphan Medicines
Blogs
Rare diseases
Approved in Europe. Available in Switzerland. The gap in between.
Blogs
Rare diseases
The real burden of treatment access for rare disease communities
Blogs
Rare diseases
Improving evidence generation in rare diseases
Events
Rare diseases
World Orphan Drug Congress USA 2026
Blogs
Rare diseases
From isolation to integration: what we learned on Rare Disease Day 2026
Thought Leadership
Rare diseases
Improving treatment access for rare disease patients and caregivers in Europe